From Tissue to Data to Commercial Value: Transformation-Triggered Governance for Human Biospecimens Beyond Informed Consent

Abstract

Background: Human biospecimens undergo continuous transformation after collection. Tumor fragments may become immortalized cell lines, genomic sequences, research datasets, artificial intelligence inputs, and commercially valuable products. However, research governance often treats informed consent as the primary normative event and focuses primarily on whether the initial authorization was sufficiently broad. Objective: This article develops Transformation-Triggered Governance (TTG), a conceptual and doctrinal legal-bioethical framework for addressing governance challenges that emerge when scientific transformations alter the risk, identifiability, relational scope, purpose, or economic significance of biospecimens. Methods: Using conceptual legal-bioethical analysis, TTG identifies five transformation triggers: biological, informational, purposive, relational, and commercial. Each trigger corresponds to proportional governance responses, including traceability, ethics review, controlled access, transparency, representation, renewed consent where appropriate, and benefit-sharing conditions when justified. The framework is examined through the HeLa cell case as a diagnostic illustration and compared with United States human subjects regulations, European data protection law, biobank fiduciary theory, genomic data governance, and community-engaged research. Results: The analysis indicates that TTG provides an intermediate approach between one-time authorization and impractical perpetual consent by shifting attention from ownership of biospecimens to circumstances that require governance adaptation. Conclusion: TTG offers an event-sensitive model for addressing downstream biospecimen transformations while distinguishing existing legal obligations from additional institutional safeguards.